The F4 idiotype is a heavy chain determinant expressed almost exclusively on IgG immunoglobulins and is highly associated with specificity for double-stranded DNA. Since high-titered F4 expression is present predominantly in sera of patients with systemic lupus erythematosus (SLE), we thought F4
Introduction
Idiotypic analyses have been useful in revealing the molecular genetics of specific antibody responses. In particular, idiotypic analyses of anti-DNA antibodies have helped reveal the structural and genetic heterogeneity that characterizes this pathogenic autospecificity. Data from several laboratories demonstrate that most idiotypic specificities present on anti-DNA antibodies are also present on normal serum Igs (1) . This observation implies the existence of a structural and genetic relationship between autoantibodies and antibodies that are presumably part of a protective immune response. However, a few idiotypes are highly restricted to DNA-binding antibodies and to individuals with SLE (2, 3) . Analysis of the molecular genetics of these idiotypes may provide clues to SLE-specific Ig expression.
We have identified three lupus-associated anti-DNA idiotypes. 3I and 8.12 are expressed in high titer in lupus sera, yet are also present on antipneumococcal antibodies from nonautoimmune individuals (4, 5) . The 3I idiotype is present on light chains, primarily those encoded by variable (V) 1 region I genes (6) , while the 8.12 idiotype is encoded exclusively by V II light chain genes (7) . Both idiotypic determinants can be encoded by germ line genes without somatic mutation, although all anti-DNA antibodies expressing these idiotypes display evidence of somatic mutation. We have interpreted these observations to mean that 3I ϩ and 8.12 ϩ antibodies can be generated routinely in response to bacterial antigens; specificity for DNA in these idiotypic systems may be generated somatically, and a defect in the regulation of autoreactive B cells in individuals with SLE may permit the survival of cells acquiring anti-DNA specificity.
The F4 idiotype is an anti-DNA-associated idiotype that is not present in the repertoire of nonautoimmune individuals or on antipneumococcal antibodies. It is present in high titer in ‫ف‬ 50% of lupus patients with anti-double-stranded (ds) DNA activity, and from 30 to 50% of anti-DNA antibodies are F4 reactive (3) . The F4 determinant is present on the heavy chain variable region, and is expressed almost exclusively on IgG antibodies (3). These observations have led us to suggest that both the F4 idiotype and DNA binding are acquired by somatic mutation, and that the F4 idiotype is intimately related to DNA specificity. As high-titered expression of this idiotype is present in SLE, a molecular genetic characterization of F4 ϩ antibodies might reveal differences in Ig variable region gene expression or in the process of somatic mutation in lupus patients that might predispose them to autoantibody production.
In this study, we characterize 10 F4 ϩ mAbs, 8 of which are novel, and 2 of which have been reported previously (6) . The molecular genetic analysis of these antibodies confirms previous serologic studies, demonstrating a strong association of the F4 idiotype with IgG isotype and with DNA binding. F4 heavy chains are encoded by V H genes that are used in protective antibody responses. A comparison of somatic mutation in these antibodies and in antibodies from nonautoimmune individuals encoded by the same V H genes shows a subtle alteration in the pattern of mutation in SLE antibodies. Somatic mutation in the SLE V H gene is targeted to a lesser extent to known mutational hot spots, suggesting an intrinsic B cell defect or an alteration in B cell activation in SLE.
Methods

Generation of F4
ϩ B cell clones (6) . No serum was available from this patient. Lymphocytes were obtained by Ficoll-Hypaque separation of whole blood and transformed using EBV as described previously (6, 8) .
Assays for isotype and for F4 idiotype
Idiotypic reactivity was tested as follows. ELISA wells were coated with purified mouse F4 mAb at 20 g/ml and incubated at 37 Њ C for 1 h. After blocking (3% BSA in PBS), culture supernatants were added for 1 h at 37 Њ C followed by peroxidase-conjugated goat antihuman IgG/IgM/IgA (Organon Teknika-Cappel, West Chester, PA). ABTS peroxidase substrate was added (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). The OD was read at 405 nm on an automated ELISA reader. 3I and 8.12 reactivity were analyzed similarly, using purified 3I or 8.12 antibody adsorbed to ELISA plates. Cells from wells containing F4 ϩ antibody in the supernatant were cloned by limiting dilution as described previously (6) , and retested for expression of the F4, 3I, and 8.12 idiotypes as described above.
Culture supernatants of F4 ϩ clones were tested for the presence of human or and , ␥ , or ␣ chains in a standard ELISA. Briefly, polyclonal goat anti-human IgM/IgG/IgA (heavy and light) antibody (Southern Biotechnology Associates, Inc., Birmingham, AL) was adsorbed to ELISA plates (Falcon 3915; Becton Dickinson Labware, Lincoln Park, NJ) for 1 h at 37 Њ C. After blocking, culture supernatants were added for 1 h at 37 Њ C, followed by peroxidase-conjugated goat anti-human IgM/IgA/IgG or (1:1,000) (Southern Biotechnology Associates, Inc.) for 1 h at 37 Њ C. ABTS peroxidase substrate was added, and the OD was read at 405 nm using an ELISA reader (Titertek Multiscan Plus; Ealabs, Finland).
Antigen specificity dsDNA binding assay. Binding to dsDNA was determined by Millipore filter assay (Millipore Corp., Bedford, MA) (6) . Briefly, supernatants were normalized for Ig concentration and tested for binding to plasmid dsDNA using nick-translated 32 P-labeled DNA made double-stranded previously by passage through a nitrocellulose filter (HAWP 45; Millipore Corp.). Supernatants were not tested for single-stranded DNA binding.
Reactivity to Smith antigen (Sm), cardiolipin, and pneumococcal polysaccharide. Direct ELISAs were performed to test for other autoantigenic specificities according to a modified protocol from Swanson et al. (9) . Briefly, wells were coated with Sm (10 g/ml) overnight at 4 Њ C. Supernatants (5 g/ml) were added for 45 min at 25 Њ C. Bound samples were detected with a goat anti-human Ig (heavy and light)-alkaline phosphatase-labeled conjugate (Southern Biotechnology Associates, Inc.) and developed using 104 substrate (Sigma Chemical Co., St. Louis, MO). Binding of cardiolipin (Fluka Chemical Co., Ronkonkoma, NY) was tested by adsorbing cardiolipin, 50 g/ml in ethanol, to Immulon II microtiter plates overnight (Dynatech Laboratories, Inc., Chantilly, VA). Samples were added for 2 h at 25 Њ C, and bound antibody was detected as described above.
To assay binding to pneumococcal polysaccharide, 4 g Pneumovax ® 23 (Merck Sharp and Dohme, West Point, PA) was coated 
Supernatants from EBV cell lines (2 g/ml) and human Ig (5 g) were incubated with 32 P-labeled dsDNA and passed through a nitrocellulose filter. Reactivity is scored as follows: Ϫ (0-100 cpm), ϩ (100-500 cpm), ϩϩ (500-1,000 cpm), and ϩϩϩ (Ͼ 1,000 cpm).
on ELISA immunoadsorbant assay/RIA high-binding plates (Costar Corp., Cambridge, MA) overnight at 4ЊC. After washing with PBSTween (0.05%) and blocking (3% BSA in PBS), supernatants were added for 1 h at 37ЊC, and the assay proceeded as described above.
Total RNA preparation
Total RNA was prepared from cell lines using guanidinium thiocyanate (6) or the Snap-O-Sol nucleic acid preparation kit (Biotecx Laboratories, Houston, TX). Northern blot analysis (6) was used to verify ϩ antibodies compared with germ line genes. These sequence data are available from EMBL/GenBank Data Libraries under accession numbers U95234 (A78), U95235 (B5-3), U95238 (B12-2), U95236 (B17-3), U95237 (H17), U95239 (M36), U95240 (MC90), and U95241 (050). (B) Nucleotide sequences of light chains of F4 ϩ antibodies compared with germ line genes. These sequence data are available from EMBL/GenBank Data Libraries under accession numbers U95242 (A78), U95243 (B5-3), U95244 (B12-2), U95248 (B17-3), U95249 (H17), U95245 (M36), U95246 (MC90), and U95247 (050).
heavy chain isotype and variable region gene family using C (5Ј-GAGGGGGAAAAGGGTTGGGGC-3Ј) and C␥ (5Ј-GCCAGG-GGGAAGACCGATGG-3Ј) oligonucleotides and genomic DNA probes representing heavy (V H ) and light (V L ) chain variable gene families (6) .
Sequence of heavy and light chain V region genes
5 g total RNA was reverse-transcribed using a C␥ oligomer and Superscript ® II RNase H reverse transcriptase (GIBCO BRL, Gaithersburg, MD). Heavy chain variable region sequences were amplified with Vent polymerase (New England Biolabs Inc., Beverly, MA) by PCR using the appropriate 3Ј constant region oligomer in conjunction with 5Ј leader oligomers for V H 1 (5Ј-ATGGACTGGACCTG-GCAGGAGTC-3Ј), V H 3 (5Ј-ATGGAGTTTGGGCTGAGCTGG-3Ј), or V H 4 (5Ј-ATGAAACACCTGTGGTTCTTC-3Ј). PCR DNA products were recovered by the Spin Bind PCR purification system (FMC BioProducts, Rockland, ME). Light chains were amplified similarly using a universal C (5Ј-AGTGTGGCCTTGTTGGCTTG-3Ј) or J 2/3 (5Ј-TAGGACGGTCAGCTTGGTCCCTCCGCCGAAAAC-CAC-3Ј) or a C (5Ј-GTTCCAGATTTCAACTGCTC-3Ј) oligomer and either 5Ј leader oligomers for V I (5Ј-CATGAGGGTCC-CCGCTCAG-3Ј), V II (5Ј-ATGAGGCTCCCTGCTCAGCTC-3Ј), or V III (5Ј-ATGGAAACCCCAGCGCAGCT-3Ј), or a 5Ј framework region (FR) 1 V3 (5Ј-TCTGTGGAGCTCCAGCCGCCCT-CAGTG-3Ј) oligomer.
PCR products were cloned into the TA cloning vector pCR ® II (Invitrogen Corp., San Diego, CA), while C products were cloned into pBluescript II or pCR script vectors (Stratagene Inc., La Jolla, CA). All were sequenced using Sequenase version 2 (USB Biologicals, Cleveland, OH). The University of Wisconsin Genetics Computer Group was used to analyze amino acid sequences as well as to compute isoelectric points. The predicted replacement (R) to silent (S) mutation ratios were determined by a computer-generated program (rsanal) developed by Joseph Mindell, Daniel Lustgarten, and Elahna Paul (Albert Einstein College of Medicine). This program analyzes the likelihood that point mutation of each nucleotide in the V region will lead to an R or S substitution. Therefore, each nucleotide is hypothetically changed to each of the other three nucleotides, and the cumulative R/S ratio is determined.
Statistics
RGYW (R ϭ A/G, Y ϭ T/C, W ϭ A/T) or trinucleotide hot spots were identified using a computer-generated program. The targeting of silent mutations to hot spots was determined using 2 ϫ 2 contingency tables (Statview computer program). P values are given for Pearson's 2 analysis.
Results
Generation and characterization of F4 ϩ lines. Sera from six lupus patients were titered for dsDNA reactivity. High-titered dsDNA reactivity (greater than the mean of control sera ϩ2SD) was observed for patients A, B, H, M, and MC (data not shown), but not for patient O. Similarly, elevated levels of F4 were observed in sera from all patients except patients O and H (data not shown). Peripheral blood lymphocytes from these patients were transformed with EBV and cloned at 1 wk, before screening for idiotype expression. In addition, splenocytes from patient D were transformed by EBV. No simultaneous serum was available for idiotypic analysis. Approximately 100 clones from each patient were screened. 21 independent idiotype-positive clones were identified, and 8 of these were maintained successfully in culture. The characteristics of these eight clones as well as two F4 ϩ antibodies (I-2a and H2F) described previously are shown in ϩ variable regions are displayed in Fig. 1 A. 7 of the 10 light chains are encoded by V genes from the V I, V II, V III, and V IV families. The three antibodies expressing light chains all use V3 genes. Nucleotide sequences of novel F4 ϩ light chains are shown in Fig. 1 B. A FASTA computer search was used to identify the germ line genes most homologous to the genes encoding the expressed F4 ϩ lupus antibodies. Nucleic and amino acid homologies to putative germ line genes are presented in Table III .
Protein sequences of F4 ϩ antibodies shown in Figs. 2 and 3 were compared to the protein sequences encoded by the putative germ line genes. Arginines in complementarity-determining region (CDR) 3 of the heavy chain have been suggested to be an important structural motif of murine DNA-binding antibodies (14) . In addition, asparagine, lysine, and glutamine have been implicated in DNA binding (15) . While there was a notable absence of arginines in CDR3 of F4 ϩ heavy chains, arginine, asparagine, and charged residues were present frequently in CDR1 and CDR2, often representing an amino acid substitution from the germ line encoded sequence.
Since nephritogenic antibodies are often cationic (16) (17) (18) , it was of interest to determine the isoelectric points of the heavy and light chain variable region sequences. Most F4 reactive heavy chains are cationic; only two are not, and these two derive from non-DNA-binding antibodies (Table IV) . In general, the germ line encoded sequence is strongly cationic, and mutation is not required to generate the charge of the heavy or light chain variable region.
Mutational analysis. Extensive somatic mutation is apparent in many of the heavy chain V region sequences (Fig. 1 A) , consistent with, although not proving, the hypothesis that mutation is necessary for expression of the F4 idiotype. All light chain V region genes are also mutated somatically (Fig. 1 B) . Since the heavy chains express the SLE-specific F4 idiotype, these were analyzed extensively to see if they might provide evidence of lupus-specific mutational processes. The R/S mutation ratios were computed over the FRs and CDRs for each variable region (Table V) . Clustering of R mutations in CDRs and a higher than random R/S ratio in CDRs are both considered evidence of antigen selection. R mutations were clustered in CDRs of F4 ϩ antibodies; 70% of all R mutations were in CDRs. While the R/S ratios in CDR1 were lower than the predicted random ratios, F4 ϩ heavy chains displayed a trend for higher than random R/S ratios in CDR2.
We sought to compare the frequency of mutation in F4 ϩ heavy chain V H genes to that in protective antibodies encoded by the same V H genes derived from nonautoimmune individuals (Table VI) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . No significant difference between the two groups was found; F4 ϩ V H genes contained 194 mutations in 10 sequences, while 437 mutations were present in 24 sequences from nonautoimmune individuals (data not shown).
Several investigators have described mutational hot spots, which appear to be targets of hypermutation (30) (31) (32) . Rogozin and Kolchanov (31) have identified sequences RGYW as potential hot spots. Recently, Smith et al. analyzed the untranslated flanking regions of Ig V genes and concluded that four trinucleotide sequences, AGC, TAC, GCT, and GTA, appear to be dominant mutational hot spots (32) . We were interested in determining whether these hot spots were targeted for mutation in SLE B cells. Therefore, we examined the frequency of mutation in hot spots (mutated/nonmutated) compared with the frequency of mutation in the rest of the gene in both SLE and non-SLE antibodies. To insure that the analysis was not confounded by altered selection in SLE, we analyzed only S mutations, which could not be subject to pressures of selection. The data show that there is a significant targeting of mutation to RGYW hot spots in antibodies derived from non-SLE individuals. 34 of 1,164 hot spots were mutated; in contrast, only 64 of 5,979 non-hot spots were mutated (P Ͻ 0.0001, Table VII ). This is in striking contrast to SLE antibodies, in which there was no significant targeting of mutation to RGYW motifs. 13 of 485 hot spots displayed S mutations, while 42 of 2,507 non-hot spots displayed S mutations (P Ͼ 0.1, Table VII ). When trinucleotide hot spots were examined, there again was a significant clustering of S mutations in hot spot motifs in antibodies from nonautoimmune individuals (P Ͻ 0.0001, Table VII ). In SLE antibodies, targeting to trinucleotide hot spots was also evident but was less than that observed for non-SLE antibodies (P Ͻ 0.01, Table VII ).
Discussion
The molecular genetic analysis of EBV-transformed F4 ϩ cells confirms the results of previous studies on F4 ϩ myeloma proteins and SLE sera (3) . All of the F4 ϩ antibodies reported here are IgG 1 , confirming the observation that F4 reactivity is highly restricted to IgG. Second, there is a strong correlation between F4 ϩ expression, cationicity, and DNA binding. In fact, our results show that all but two F4 ϩ heavy chains in this study are cationic, and of the eight cationic F4 ϩ heavy chains, seven bind dsDNA. Sequence analysis revealed that the germ line genes used to encode F4 ϩ antibodies encode cationic sequences, and that somatic mutation is not critical for their charge. Similarly, Harada et al. have found that the very cationic light chains found in anti-DNA antibodies are encoded by a V gene which in its germ line configuration encodes a highly cationic sequence (17) . Furthermore, an isolated heavy chain encoded by a V H 4 variable region gene has been shown to bind dsDNA, and this heavy chain also derives from a germ line gene that is cationic (33) . Antibody 050 has seven of nine CDR2 residues in common with this isolated V H 4 heavy chain.
Since F4 is a lupus-associated idiotype (3) (60% of lupus patients have elevated titers of F4 ϩ Igs in their sera), it was possible that it would be encoded by a single V H gene. However, sequence analysis showed that several V H gene families can encode F4 ϩ heavy chains. The fact that most of the antibodies reported here are encoded by V H 3 genes probably does not reflect an idiotypic bias for V H 3, but rather the predominant use of V H 3 genes in human peripheral blood B cells (34). Furthermore, the V H genes used to encode F4 ϩ antibodies are expressed in the repertoire of nonautoimmune individuals, suggesting that the F4 idiotype is generated by convergent patterns of somatic mutation and not by usage of a single V H gene or by an infrequently used subset of V H genes.
No cell line expresses a J H 1 or J H 2 gene segment. While it is tempting to speculate that the absence of J H 1 and J H 2 suggests that receptor editing of heavy chain genes occurs frequently in individuals with SLE, studies of 34 antibodies to foreign antigens derived from nonautoimmune individuals also show that only one anti-HIV antibody (29) and one antibody-specific Haemophilus influenzae type B (22) are encoded by a J H 1 or J H 2 segment. Previous analysis of 97 autoantibodies (35) showed that only 3 antibodies are encoded by J H 1 or J H 2 gene segments. The absence of these gene segments appears to be a general characteristic of the human heavy chain repertoire, perhaps due to recombination signal sequences that do not favor rearrangement. Further studies of unexpressed VDJ sequences are needed to address this question.
While F4 ϩ heavy chains can associate with light chains, most F4-reactive antibodies possess light chains, and all of these are 3I ϩ . This confirms a previous analysis of myeloma proteins that demonstrated a significant association of F4 and 3I reactivity. We looked for indirect evidence of receptor editing by examining whether any V sequences were encoded by upstream V segments (J distal) and downstream J segments. Three F4 ϩ antibodies (A78, M36, and MC90) use upstream V genes; however, these do not express downstream J segments. Only the B12-2 non-DNA-binding antibody expresses a Jdistal V with a downstream J segment (J 4). This result concurs with those of others suggesting that there is little evidence for receptor editing of light chains in these autoreactive B cells (36) . Perhaps it is a lack of editing that helps predispose some individuals to the production of autoreactive B cells. In support of this argument are data showing the failure of SLE B cells to edit the A30-J 2-C rearrangement, which is rarely expressed in nonautoimmune individuals but has been shown to exhibit nephritogenic potential in SLE individuals (37) . Sequence analysis confirms the hypothesis that F4 ϩ antibodies are mutated somatically. In the heavy chain variable regions, mutations in CDR2 are more prevalent than mutations in CDR1. This is consistent with other studies showing an increased frequency of somatic mutation in CDR2 of V H 3 and V H 4 genes encoding autoantibodies (18, 38) . Radic and Weigert have suggested that CDR2 of the heavy chain plays an important role in DNA binding, and a large number of murine anti-DNA antibodies also display extensive mutation of CDR2 in the heavy chain V region (39) .
Because F4 ϩ antibodies are mutated, and because they are present almost uniquely in SLE serum, they offer the opportunity to study the pattern of somatic mutation in V H genes used by lupus antibodies. While other SLE-associated idiotypes like 3I and 8.12 are expressed on protective antibodies in normal serum, F4 ϩ antibodies do not appear to be part of a protective response and are not present in normal serum. Therefore, we reasoned that the analysis of somatic mutation in F4 ϩ heavy chains might reveal a population of V H genes displaying SLEspecific aspects of somatic mutation.
Analysis of R and S mutations displayed a clustering of R mutations in CDRs and a trend toward a higher than random R/S ratio in CDRs. These observations are more consistent with antigen selection than polyclonal activation, yet it is not possible from these studies to know whether the selecting antigen is a self or foreign antigen.
Smith and colleagues reported recently no difference in use of trinucleotide mutational hot spots between autoantibodies and anti-foreign antibodies in mice (32) ; however, they analyzed autoantibodies derived from MRL/lpr mice. MRL/lpr mice are autoimmune due to a defect in fas gene expression (40), which would not be expected to be involved in the process of somatic mutation. Our analysis reveals the same frequency of mutation in V H genes encoding F4 ϩ heavy chains as in these genes encoding protective antibodies. However, we do find evidence for decreased targeting of somatic mutation to mutational hot spots when RGYW motifs are examined. When trinucleotide motifs are examined, there remains a targeting of somatic mutation to hot spots, but it is less than that seen in non-lupus heavy chains. This observation suggests that mutation can be uncoupled from targeting to hot spots. We would speculate that one complex is needed for mutation to occur, and that additional proteins are needed to target mutation to particular DNA sequences.
These results are similar to other studies in our laboratory which found that germinal center B cells of mice constitutively expressing bcl-2 show no decrease in frequency of somatic mutation of Ig genes, but a decreased targeting of mutation to putative mutational hot spots (41) . Recent studies have shown that expression of bcl-2 inhibits progression through the cell cycle (42, 43) . Possibly, the alteration in cell cycle kinetics leads to a change in the process of somatic mutation. More likely, constitutive expression of bcl-2 may alter gene expression in B cells and lead to an uncoupling of mutation from targeting to hot spots. Constitutive expression of bcl-2 or other alterations in B cell activation might affect expression of proteins needed to target mutation to hot spots. While the data remain inconclusive, it has been suggested that SLE B cells overexpress bcl-2 (44, 45) .
It is possible, given the data presented, that there is a defect in the machinery of somatic mutation in SLE B cells, but it is more likely that the altered pattern of somatic mutation reflects a difference in B cell activation that may determine thresholds for negative selection. Alterations in B cell gene expression might affect both the targeting of somatic mutation and thresholds for negative selection. For example, increased expression of bcl-2, reported to occur in SLE B cells (44) , affects both resistance to apoptosis and the targeting of somatic mutation to hot spot motifs. Alternatively, other changes in gene expression might lead to an uncoupling of mutation from targeting to hot spots. Because our analysis of mutation focuses exclusively on S mutations, we can conclude that the decreased frequency of mutation in hot spots is not a function of altered selection in SLE. We would speculate that the abnormal pattern of mutation is not itself responsible for the autospecificities that are present. Rather, we believe as stated above that overexpression of bcl-2, or some other change in B cell activation, is responsible for both the altered mutational pattern characterized by an uncoupling of mutation from targeting to hot spots, and the altered selection of B cells. We believe that SLE B cells may undergo germinal center maturation while in a different activation state. Taken together, these data might suggest that autospecificities in SLE arise due to a lack of negative selection of B cells acquiring autoreactivity through somatic mutation, rather than an antigen-specific activation of autoreactive cells. B cells in SLE may have an altered pattern of gene expression that leads to enhanced survival and an uncoupling of mutation from hot spot targeting. P values are determined by a 2 analysis of S mutations in hot spots over total hot spots, compared with S mutations in non-hot spots over total non-hot spots. This represents the targeting of mutations to hot spot motifs.
